多西环素治疗恶性实体肿瘤的研究进展

Research progress of doxycycline in the treatment of malignant solid tumors

恶性肿瘤是威胁人类生命与健康的重要疾病,严重威胁经济的发展和社会稳定。治疗耐药和远处转移是恶性实体肿瘤死亡的主要原因,也是目前临床治疗的关键难题。近年来,一些具有抑制细胞活性的抗生素被注册为抗肿瘤药物,给临床治疗带来希望。多西环素具有良好的组织穿透性,口服吸收良好,没有明显的组织毒性。并且,多项实验研究表明多西环素具有抗肿瘤作用。但由于效能低、副作用多等局限性,目前暂时未用于临床肿瘤的治疗。因此,本文拟对多西环素治疗恶性实体肿瘤的研究做一综述,总结具体作用、机制和现阶段面临的问题,并对多西环素治疗恶性实体肿瘤的应用前景提出展望。

Malignant tumours are important diseases that threaten human life and health and pose a serious threat to economic development and social stability.Treatment resistance and distant metastasis are the main reasons for the high mortality rate of malignant solid tumours and are currently the key challenges in clinical treatment.In recent years,a number of antibiotics with cytostatic activity have been registered as antitumour agents,offering hope for clinical treatment.Doxycycline has good tissue penetration,is well absorbed orally and has no significant tissue toxicity.Moreover,several experimental studies have shown that doxycycline has anti-tumour effects.However,due to the limitations of low efficacy and many side effects,it is not used in clinical tumour treatment for the time being.Therefore,this paper aims to review the research on doxycycline in the treatment of malignant solid tumours,summarise the specific effects,mechanisms and problems faced at this stage,and provide an outlook on the application of doxycycline in the treatment of malignant solid tumours.